Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

TULIP Trials Show Clinical Benefit of Anifrolumab for SLE

Publish date:: December 5, 2019

Key clinical point: Anifrolumab provides clinical benefit in moderate to severe SLE.

Major finding: BICLA response rates in TULIP-2 were 47.8% with anifrolumab versus 31.5% with placebo.

Study details: The phase 3 TULIP-1 and -2 trials involved a total of 819 patients.

Disclosures: The TULIP-1 and -2 trials were sponsored by AstraZeneca. Dr. Furie And Dr. Morand both reported grant/research support and consulting fees from AstraZeneca, as well as speaker’s bureau participation for AstraZeneca.

Citation:

Furie RA et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract 1763; Morand EF et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract L17.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Rheumatology

Osteoporosis prevalence in PsA similar to general population,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Oral steroids plus PPIs increase osteoporotic fracture risk in RA patients,

Etanercept may not help some with suspected nonradiographic axial spondyloarthritis,